Ancora Advisors’s NovoCure NVCR Stock Holding History

Ancora Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-749	Closed	-$8.16K	–	2250
2026 Q1	$8.16K	Sell	749 -292	-28%	-$3.65K	﹤0.01%	1829
2025 Q4	$13.5K	Buy	+1,041	New	+$13.4K	﹤0.01%	1698
2022 Q4	–	Sell	-6	Closed	–	–	1899
2022 Q3	$0	Hold	6	–	–	﹤0.01%	2129
2022 Q2	$0	Buy	+6	New	+$452	﹤0.01%	2304
2021 Q2	–	Sell	-50	Closed	-$7K	–	1983
2021 Q1	$7K	Buy	+50	New	+$7.91K	﹤0.01%	1511
2020 Q2	–	Sell	-150	Closed	-$10K	–	1402
2020 Q1	$10K	Buy	+150	New	+$11.9K	﹤0.01%	1189

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Ancora Advisors's NVCR Position: Q2 2026 in Review

Ancora Advisors sold out of NovoCure (NVCR) in Q2 2026, closing a stake of 749 shares — an estimated $8.16K sold.

Ancora Advisors first reported a position in NVCR in Q1 2020 and held it in 6 quarters. The position peaked at $13.5K in Q4 2025. 218 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Ancora Advisors reported no remaining NovoCure position as of Q2 2026 after selling out during the quarter.
Ancora Advisors sold 749 NovoCure shares in Q2 2026, an estimated $8.16K.
Ancora Advisors first reported a position in NovoCure in Q1 2020 and held it in 6 quarters.
Ancora Advisors's NovoCure position peaked at $13.5K in Q4 2025.
218 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Ancora Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.